Biologics News
AUGTYRO™ (Repotrectinib), FDA Approved for Treatment of AdvancedROS1-Positive & NTRK-Positive NSCLC, Available at Biologics by McKessonSpecialty Pharmacy in Limited Distribution Network
Cary, N.C., July 1, 2025 – Effective July 1st, Bristol Myers Squibb Co. has reduced its specialty pharmacy network for
IBTROZI™ (Taletrectinib), FDA-Approved Treatment, Available at Biologics by McKesson
Cary, N.C. , June 11, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease
EMRELIS™ (telisotuzumab vedotin-tllv), FDA Approved for Treatment of Adult Patients with Previously Treated Non-Small Cell Lung Cancer, Available Exclusively at Biologics by McKesson
Cary, N.C. , May 20, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease
AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets,) FDA Approved for the Treatment of Adult Patients with KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer who have Received Prior Systemic Therapy, Available at Biologics by McKesson
Cary, N.C. , May 9, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease
VANRAFIA (atrasentan), FDA Approved for Adults with Immunoglobulin A Nephropathy, Available at Biologics by McKesson
CARY, N.C., April 3, 2025—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected
GOMEKLI FDA Approved for Treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), Available at Biologics by McKesson
CARY, N.C., FEBRUARY 18, 2025—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been